The Europe Theranostics Market would witness market growth of 14.8% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Theranostics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $338.8 million by 2030. The UK market is exhibiting a CAGR of 13.7% during (2023 - 2030). Additionally, The France market would experience a CAGR of 15.7% during (2023 - 2030).
Theranostic agents, such as radiopharmaceuticals and targeted therapies, deliver therapeutic payloads directly to cancer cells while sparing healthy tissues, enhancing treatment efficacy, and minimizing side effects. Imaging techniques such as echocardiography, cardiac MRI, and computed tomography angiography (CTA) enable visualization of cardiac anatomy, function, and blood flow, aiding in diagnosing coronary artery disease, myocardial infarction, and heart failure.
Biomarker-based assays, including troponin and B-type natriuretic peptide (BNP), provide prognostic information and risk stratification for cardiovascular events. Theranostic strategies help identify high-risk patients for adverse cardiovascular outcomes, enabling personalized treatment plans and interventions to improve patient outcomes. Additionally, these also have applications in neurology for the diagnosis and management of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and stroke.
As per the Eurostat, the high incidence of cardiovascular diseases (CVDs) in Europe drives the demand for advanced diagnostic tools and techniques for early detection, risk assessment, and disease monitoring. The standardized death rate for cerebrovascular diseases in 2020 in Bulgaria (which had the highest rate among the EU Member States) was 8.4 times higher than in France. Therefore, the growing prevalence of cardiovascular disease in the region propels the market’s growth.
Based on End User, the market is segmented into Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers. Based on Product, the market is segmented into Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services. Based on Application, the market is segmented into Prostate Cancer, Bone Metastasis, Other Cancers, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Theranostics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $338.8 million by 2030. The UK market is exhibiting a CAGR of 13.7% during (2023 - 2030). Additionally, The France market would experience a CAGR of 15.7% during (2023 - 2030).
Theranostic agents, such as radiopharmaceuticals and targeted therapies, deliver therapeutic payloads directly to cancer cells while sparing healthy tissues, enhancing treatment efficacy, and minimizing side effects. Imaging techniques such as echocardiography, cardiac MRI, and computed tomography angiography (CTA) enable visualization of cardiac anatomy, function, and blood flow, aiding in diagnosing coronary artery disease, myocardial infarction, and heart failure.
Biomarker-based assays, including troponin and B-type natriuretic peptide (BNP), provide prognostic information and risk stratification for cardiovascular events. Theranostic strategies help identify high-risk patients for adverse cardiovascular outcomes, enabling personalized treatment plans and interventions to improve patient outcomes. Additionally, these also have applications in neurology for the diagnosis and management of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and stroke.
As per the Eurostat, the high incidence of cardiovascular diseases (CVDs) in Europe drives the demand for advanced diagnostic tools and techniques for early detection, risk assessment, and disease monitoring. The standardized death rate for cerebrovascular diseases in 2020 in Bulgaria (which had the highest rate among the EU Member States) was 8.4 times higher than in France. Therefore, the growing prevalence of cardiovascular disease in the region propels the market’s growth.
Based on End User, the market is segmented into Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers. Based on Product, the market is segmented into Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services. Based on Application, the market is segmented into Prostate Cancer, Bone Metastasis, Other Cancers, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Bayer AG
- GE HealthCare Technologies, Inc.
- Siemens Healthineers AG (Siemens AG)
- Cardinal Health, Inc.
- Canon, Inc.
- Clarity Pharmaceuticals Ltd
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- Telix Pharmaceuticals Limited
- ABX advanced biochemical compounds GmbH
Market Report Segmentation
By End User- Hospitals & Cancer Care Centers
- Theranostics Centers
- Research & Academic Centers
- Radiopharmaceuticals
- Diagnostic Imaging
- IVD/Biomarker Screening
- Software & Services
- Prostate Cancer
- Bone Metastasis
- Other Cancers
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Theranostics Market by End User
Chapter 5. Europe Theranostics Market by Product
Chapter 6. Europe Theranostics Market by Application
Chapter 7. Europe Theranostics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bayer AG
- GE HealthCare Technologies, Inc.
- Siemens Healthineers AG (Siemens AG)
- Cardinal Health, Inc.
- Canon, Inc.
- Clarity Pharmaceuticals Ltd
- Koninklijke Philips N.V.
- Thermo Fisher Scientific, Inc.
- Telix Pharmaceuticals Limited
- ABX advanced biochemical compounds GmbH
Methodology
LOADING...
